Actively Recruiting
IMPACT-AML Randomized Trial Comparing Low and High Intensity Therapies in Relapsed or Refractory Acute Myeloid Leukemia
Led by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Updated on 2026-10-27
339
Participants Needed
51
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing high intensity reinduction chemotherapy with low intensity therapies in patients with relapsed or refractory Acute Myeloid Leukemia AML who are in their first or second relapse. This pragmatic, randomized clinical trial aims to evaluate the clinical benefits and safety of these treatment approaches. The study is funded by the European Commission and seeks to provide real-world insights into personalized treatment options for AML. Participants will be assigned to one of two groups one receiving low intensity therapies, which involve innovative and targeted drugs alone or in combinations with less-toxic agents the other receiving high intensity chemotherapy regimens, including various high-dose chemotherapy combinations. Both treatment types may be combined with antibodies or targeted agents as per local practice. The study follows a clinical-oriented approach to compare these strategies. During the trial, participants will undergo treatment and regular evaluations to monitor their response, quality of life, and safety over a period of 36 months. Researchers will assess event-free survival, overall survival, treatment responses, patient-reported quality of life, and safety outcomes. The study design includes randomization without blinding and covers a follow-up period extending up to the study completion in 2028.
CONDITIONS
Brief Title
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Research Team
O
Oriana Nanni
I
Impact-aml coord Impact-aml coord
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here